Events
Priavoid is heading to BIO-Europe Spring, and we are looking forward to connecting with partners and peers focused on the next generation of disease-modifying therapies for Alzheimer’s and Parkinsons Disease
From March 23–25, our CEO Philipp Bürling will be on site in Lisbon and available for meetings.
If you are attending BIO-Europe Spring and would like to learn more about our clinical candidate PRI-002, our versatile disease-modifying approach, or our pipeline strategy, we would be excited to connect.
About Priavoid
Priavoid’s novel class of orally available all-D-peptide therapeutics detangle neurotoxic oligomer species to inhibit and reverse disease-specific protein aggregation in neurodegenerative disorders. We aim to establish clinical proof-of-concept through our lead program, PRI-002, which will complete a Phase 2 trial in Alzheimer’s disease in 2026. Priavoid has built a focused pipeline of detangler compounds that are non-immunogenic and reach their oligomer targets in the brain and inside the affected cells. Our goal is to develop disease-modifying therapies that address the underlying biology of neurodegeneration and drive meaningful clinical benefit for patients.